ClinicalTrials.gg
RecruitingNCT06476119OPTImaLUpdated Nov 16, 2026

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

An observational study in Breast Cancer Stage I and Triple Negative Breast Cancer (TNBC), sponsored by The Netherlands Cancer Institute. Recruiting at 28 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Netherlands Cancer Institute · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 16, 2026Sponsor changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
490
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands — 8 open to participants now, 14 under way, 4 of them phase 3. Triple Negative Breast Neoplasms · Netherlands.

Started
2025
with 3 others
Observational
Only one
of the 32
Primary completion
2032-09
later than 13 of 13 live
Registered
28th of 32
by date
Lead sponsor
2 of 32
The Netherlands Cancer Institute

Among the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands, this one is one of 4 that started in 2025, is the only observational one, reaches primary completion later than 13 of the 13 other live ones, and was the 28th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

8 of the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consultation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not.

03

Conditions studied

  • Breast Cancer Stage I
  • Triple Negative Breast Cancer (TNBC)

Browse trials for

Keywords

  • High (stromal Tumor-Infiltrating-Lymphocytes) sTIL score
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 490 is above the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

The Netherlands Cancer Institute is the lead sponsor of 231 studies on the registry; 66 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with pathological stage I TNBC (pT1a/b/cN0) and a high sTIL score (defined as ≥50% for patients ≥40 years; ≥75% for patients \<40 years)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male patients;
  • >=18 years;
  • Written ;
  • TNBC (defined as: invasive carcinoma; ER/PR expression 0-9%; Human Epidermal Growth Factor Receptor 2 [] negative [0, 1+ or 2+ on immunohistochemistry, without HER2 amplification on in-situ hybridization]) on the diagnostic and the surgical specimen;
  • Pathological stage I TNBC (according to the TNM staging 8th edition):

    • pT1a/b/c (≤2 cm), confirmed by an invasive component of ≤2 cm on the surgical specimen (microinvasive disease [pT1mi, ≤1 mm) is not allowed);
    • pN0, confirmed by absence of malignant cells in the sentinel lymph node or any other lymph node after surgery (isolated tumor cells [N0(i+)] are not allowed);
  • No evidence of nodal or distant (cN0M0) on pre and/or postoperative imaging examinations (performed following local/national guidelines, but must include an 18F-fluorodeoxyglucose positron emission tomography/computed tomography [18F-FDG-PET/CT, at least from skull base to upper legs] or computed tomography [CT] of neck/chest/abdomen/pelvis [CT only if 18F-FDG-PET/CT would not be available; 18F-FDG-PET/CT mandatory in the Netherlands]);
  • sTIL score of ≥50% for patients ≥40 years at the time of TNBC diagnosis and ≥75% for patients \<40 years at the time of TNBC diagnosis on an H\&E FFPE tissue slide on the surgical specimen, according to International Immuno-Oncology Biomarker Working Group on Breast Cancer (formerly International TILs Working Group) guidelines, by local and central review
  • Has undergone curative breast surgery (breast-conserving surgery or mastectomy and surgical axillary staging [including at least sentinel lymph node procedure]);
  • Absence of recurrence between curative breast surgery and expression of patient preference;
  • Eligible for radiotherapy (if indicated).

Exclusion criteria

Exclusion Criteria:

  • Prior disease history of invasive and/or non-invasive breast cancer, or ongoing treatment for invasive and/or non-invasive breast cancer;
  • Multifocal, multicentric or bilateral breast cancer at the time of screening;
  • Administration of systemic therapy;
  • Presence of lymphovascular invasion on the diagnostic and/or the surgical specimen;
  • Other invasive within 5 years prior to inclusion, with the exception of ade-quately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤6 prostate cancer;
  • Uncontrolled severe illness or medical condition;
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the in the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
490 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Optimisation cohort

    patients will be treated with surgery and adjuvant radiotherapy following local/national guidelines, while chemotherapy will be omitted

    Other: No adjuvant chemotherapy

  • Control cohort

    patients will be treated with surgery, adjuvant radiotherapy and adjuvant chemotherapy following local/national guidelines

    Drug: Adjuvant chemotherapy

Interventions

  • DrugAdjuvant chemotherapy

    adjuvant chemotherapy according to local/ national guidelines

    Also known as: according to local/ national guidelines

  • OtherNo adjuvant chemotherapy

    no adjuvant chemotherapy

07

What researchers measure

Primary outcomes

  1. Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population

    Number of patients with distant recurrence or death in per-protocol population of the optimisation cohort

    Time frame: up to 96 months after inclusion of the last patient

Secondary outcomes

  1. Disease recurrence Free Interval (DRFI) - optimalisation cohort intention to treat population

    Number of patients with distant recurrence or death in intention to treat population of the optimisation cohort

    Time frame: up to 96 months after inclusion of the last patient

  2. Disease recurrence Free Interval (DRFI) - control cohort

    Number of patients with distant recurrence or death in control cohort

    Time frame: up to 96 months after inclusion of the last patient

  3. Invasive disease-free survival (IDFS) - optimalisation cohort per-protocol population

    Number of patients with breast tumor recurrence or death in the per-protocol population of the optimisation cohort

    Time frame: up to 96 months after inclusion of the last patient

  4. Invasive disease-free survival (IDFS) - optimalisation cohort intention-to-treat population

    Number of patients with breast tumor recurrence or death in the the intention-to-treat population of the optimisation cohort

    Time frame: up to 96 months after inclusion of the last patient

  5. Invasive disease-free survival (IDFS) - control cohort

    Number of patients with breast tumor recurrence or death in the control cohort

    Time frame: up to 96 months after inclusion of the last patient

  6. disease recurrence free survival (DRFS) - optimalisation cohort per-protocol population

    time between inclusion and first distant recurrence or death from any cause in the per-protocol population of the optimisation cohort

    Time frame: up to 96 months after inclusion of the last patient

  7. disease recurrence free survival (DRFS) - optimalisation cohort the intention-to-treat population

    time between inclusion and first distant recurrence or death from any cause in the intention-to-treat population of the optimisation cohort population of the optimisation cohort

    Time frame: up to 96 months after inclusion of the last patient

  8. disease recurrence free survival (DRFS) - control cohort

    time between inclusion and first distant recurrence or death from any cause in the control cohort

    Time frame: up to 96 months after inclusion of the last patient

  9. Recurrence-free survival (RFS) - optimalisation cohort per-protocol population

    time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the per-protocol population of the optimisation cohort;

    Time frame: up to 96 months after inclusion of the last patient

  10. Recurrence-free survival (RFS) - optimalisation cohort the intention-to-treat population

    time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the the intention-to-treat population of the optimisation cohort;

    Time frame: up to 96 months after inclusion of the last patient

  11. Recurrence-free survival (RFS) - control cohort

    time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the control cohort;

    Time frame: up to 96 months after inclusion of the last patient

  12. Overal Survival (OS) - optimalisation cohort per-protocol population

    time between inclusion and death from any cause in the per-protocol population of the optimisation cohort;

    Time frame: up to 96 months after inclusion of the last patient

  13. Overal Survival (OS) - optimalisation cohort intention-to-treat population

    time between inclusion and death from any cause in the the intention-to-treat population of the optimisation cohort;

    Time frame: up to 96 months after inclusion of the last patient

  14. Overal Survival (OS) - control cohort

    time between inclusion and death from any cause in the control cohort;

    Time frame: up to 96 months after inclusion of the last patient

  15. Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-C30

    Difference in QoL assessed with the EORTC QLQ-C30 questionnaires between the optimisation and the control group. A higher score indicates a higher symptom burden.

    Time frame: up to 2 years after inclusion

  16. Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-BR45

    Difference in QoL assessed with the EORTC QLQ-BR45 questionnaires between the optimisation and the control group. A higher score indicates a higher symptom burden.

    Time frame: up to 2 years after inclusion

  17. Fear of recurrence

    Assessed with questionnaires to determine the difference in optimisation and control group

    Time frame: up to 2 years after inclusion

  18. Worries about health

    Assessed with questionnaires to determine the difference in optimisation and control group. A higher score indicates a higher symptom burden.

    Time frame: up to 2 years after inclusion

  19. Cost effectiveness measured by quality-adjusted-life years (QALYs)

    Measured per Quality-Adjusted Life Years (QALYs)

    Time frame: up to 2 years after inclusion

  20. Cost effectiveness measured per incremental cost-effectiveness ratio (ICER)

    Measured per incremental cost-effectiveness ratio (ICER)

    Time frame: up to 2 years after inclusion

08

Study locations

18 of 28 sites recruiting
  • Medical spectrum Twente
    Enschede, Overijssel 7500 KA, Netherlands
    Recruiting
    • M Wymenga, MD · Contact
    • M Wymenga, MD · Principal investigator
  • Noordwest Ziekenhuisgroep
    Alkmaar, Netherlands
    Not yet recruiting
    • S Vrijaldenhoven, MD · Contact
    • S Vrijaldenhoven, MD · Principal investigator
  • Flevoziekenhuis
    Almere Stad, Netherlands
    Not yet recruiting
    • S.A.L. Bartels, MD · Contact
    • S.A.L. Bartels, MD · Principal investigator
  • Meander Medisch Centrum
    Amersfoort, Netherlands
    Recruiting
    • J M Baas, MD · Contact
    • J M Baas, MD · Principal investigator
  • Antoni van Leeuwenhoek
    Amsterdam, 1066 CX, Netherlands
    Recruiting
    • Marleen Kok, MD · Contactm.kok@nki.nl · +3120512
    • Ingrid AM Mandjes, MSc · Contacti.mandjes@nki.nl · +3120512
    • Marleen Kok, MD · Principal investigator
  • Onze Lieve Vrouwe Gasthuis (OLVG)
    Amsterdam, Netherlands
    Recruiting
    • B Flameling, MD · Contact
    • B Flameling, MD · Principal investigator
  • Rijnstate
    Arnhem, Netherlands
    Recruiting
    • K Beelen, MD · Contact
    • K Beelen, MD · Principal investigator
  • Amphia ziekenhuis
    Breda, Netherlands
    Recruiting
    • J Heijns, MD · Contact
    • J Heijns, MD · Principal investigator
  • Deventer Ziekenhuis
    Deventer, Netherlands
    Recruiting
    • L. Kessels, MD, PhD · Contact
    • L. Kessels, MD, PhD · Principal investigator
  • Ziekenhuis Gelderse Vallei
    Ede, Netherlands
    Recruiting
    • M Verstappen, MD · Contact
    • M Verstappen, MD · Principal investigator
  • Catharina Ziekenhuis
    Eindhoven, Netherlands
    Recruiting
    • R-J Schipper, MD · Contact
    • R-J Schipper, MD · Principal investigator
  • Jeroen Bosch ziekenhuis
    Eindhoven, Netherlands
    Recruiting
    • J Tol, MD · Contact
    • J Tol, MD · Principal investigator
  • St. Jansdal
    Harderwijk, Netherlands
    Recruiting
    • J A Ropela, MD · Contact
    • J A Ropela, MD · Principal investigator
  • Ziekenhuisgroep Twente
    Hengelo, Netherlands
    Recruiting
    • E Siemerink, MD · Contact
    • E Siemerink, MD · Principal investigator
  • Tergooi ziekenhuizen
    Hilversum, Netherlands
    Recruiting
    • A Willemsen, MD · Contact
    • A Willemsen, MD · Principal investigator
  • Spaarne Gasthuis
    Hoofddorp, Netherlands
    Recruiting
    • B de Valk, MD · Contact
    • B de Valk, MD · Principal investigator
  • Dijklander ziekenhuis
    Hoorn, Netherlands
    Not yet recruiting
    • M M Vleugel, MD · Contact
    • M M Vleugel, MD · Principal investigator
  • MCL
    Leeuwarden, 8934 AD, Netherlands
    Not yet recruiting
    • L Hamming, MD · Contact
    • L Hamming, MD · Principal investigator
  • LUMC
    Leiden, Netherlands
    Not yet recruiting
    • J Kroep, MD · Contact
    • J Kroep, MD · Principal investigator
  • MUMC
    Maastricht, Netherlands
    Not yet recruiting
    • M de Boer, MD · Contact
    • M de Boer, MD · Principal investigator
  • St. Antonius ziekenhuis
    Nieuwegein, Netherlands
    Recruiting
    • M J Agterof, MD · Contact
    • M J Agterof, MD · Principal investigator
  • Radboud UMC
    Nijmegen, 6225GA, Netherlands
    Not yet recruiting
    • E Kuip, MD · Contact
    • E Kuip, MD · Principal investigator
  • Erasmus Medical Center Cancer Institute
    Rotterdam, 3015CE, Netherlands
    Not yet recruiting
    • A Jager, MD · Contact
    • A Jager, MD · Principal investigator
  • Franciscus Gasthuis & Vlietland
    Schiedam, Netherlands
    Recruiting
    • J.M. Zuetenhorst, dr. · Contact
  • Zuyderland Medisch Centrum
    Sittard-Geleen, 6162 BG, Netherlands
    Not yet recruiting
    • F van den Berkmortel, MD · Contact
    • F van den Berkmortel, MD · Principal investigator
  • Haaglanden Medisch Centrum
    The Hague, Netherlands
    Recruiting
    • R. Oosterkamp, MD, PhD · Contact
    • R. Oosterkamp, MD, PhD · Principal investigator
  • VieCuri Medisch Centrum voor Noord-Limburg
    Venlo, Netherlands
    Not yet recruiting
    • E Boon, MD · Contact
    • E Boon, MD · Principal investigator
  • Isala
    Zwolle, Netherlands
    Recruiting
    • A Honkoop, MD · Contact
    • A Honkoop, MD · Principal investigator
09

References and documents

Individual participant data

Plan to share: No — no IPD plan

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Sep 2032, 89 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Jun 26, 2024
StartActual
Apr 15, 2025
Primary completionEst.
Sep 15, 2032
CompletionEst.
Sep 15, 2034
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (4 Netherlands)
  • Flevoziekenhuis · Almere Stad, Netherlands
  • Radboud UMC · Nijmegen, Netherlands
  • Zuyderland Medisch Centrum · Sittard-Geleen, Netherlands
  • Haaglanden Medisch Centrum · The Hague, Netherlands
Show 4 removed
  • Zuyderland Medisch Centrum · Sittard-Geleen, Netherlands
  • Flevoziekenhuis · Almere, Netherlands
  • Haaglanden Medisch Centrum · Den Haag, Netherlands
  • Radboud UMC · NIjmegen, Netherlands
Nov 16, 2026
Site contacts
Changed at 23 sites. See the sites
Show 23 sites
  • Medical spectrum Twente · Enschede, NetherlandsContact added (no phone or email listed)
  • Noordwest Ziekenhuisgroep · Alkmaar, NetherlandsContact added (no phone or email listed)
  • Meander Medisch Centrum · Amersfoort, NetherlandsContact added (no phone or email listed)
  • Antoni van Leeuwenhoek · Amsterdam, NetherlandsContact person changed (no phone or email listed)
  • Onze Lieve Vrouwe Gasthuis (OLVG) · Amsterdam, NetherlandsContact added (no phone or email listed)
  • Rijnstate · Arnhem, NetherlandsContact added (no phone or email listed)
  • Amphia ziekenhuis · Breda, NetherlandsContact added (no phone or email listed)
  • Deventer Ziekenhuis · Deventer, NetherlandsContact added (no phone or email listed)
  • Ziekenhuis Gelderse Vallei · Ede, NetherlandsContact added (no phone or email listed)
  • Catharina Ziekenhuis · Eindhoven, NetherlandsContact added (no phone or email listed)
  • Jeroen Bosch ziekenhuis · Eindhoven, NetherlandsContact added (no phone or email listed)
  • St. Jansdal · Harderwijk, NetherlandsContact added (no phone or email listed)
  • Ziekenhuisgroep Twente · Hengelo, NetherlandsContact added (no phone or email listed)
  • Tergooi ziekenhuizen · Hilversum, NetherlandsContact added (no phone or email listed)
  • Spaarne Gasthuis · Hoofddorp, NetherlandsContact added (no phone or email listed)
  • Dijklander ziekenhuis · Hoorn, NetherlandsContact added (no phone or email listed)
  • MCL · Leeuwarden, NetherlandsContact added (no phone or email listed)
  • LUMC · Leiden, NetherlandsContact added (no phone or email listed)
  • MUMC · Maastricht, NetherlandsContact added (no phone or email listed)
  • St. Antonius ziekenhuis · Nieuwegein, NetherlandsContact added (no phone or email listed)
  • Erasmus Medical Center Cancer Institute · Rotterdam, NetherlandsContact added (no phone or email listed)
  • VieCuri Medisch Centrum voor Noord-Limburg · Venlo, NetherlandsContact added (no phone or email listed)
  • Isala · Zwolle, NetherlandsContact added (no phone or email listed)
Nov 16, 2026
Sponsor
Collaborators added: Dutch Cancer Society
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Netherlands)
    • Flevoziekenhuis · Almere Stad, Netherlands
    • Radboud UMC · Nijmegen, Netherlands
    • Zuyderland Medisch Centrum · Sittard-Geleen, Netherlands
    • Haaglanden Medisch Centrum · The Hague, Netherlands
    Show 4 removed
    • Zuyderland Medisch Centrum · Sittard-Geleen, Netherlands
    • Flevoziekenhuis · Almere, Netherlands
    • Haaglanden Medisch Centrum · Den Haag, Netherlands
    • Radboud UMC · NIjmegen, Netherlands
    Sponsor Collaborators added: Dutch Cancer Society
    Site contacts Changed at 23 sites. See the sites
    Show 23 sites
    • Medical spectrum Twente · Enschede, NetherlandsContact added (no phone or email listed)
    • Noordwest Ziekenhuisgroep · Alkmaar, NetherlandsContact added (no phone or email listed)
    • Meander Medisch Centrum · Amersfoort, NetherlandsContact added (no phone or email listed)
    • Antoni van Leeuwenhoek · Amsterdam, NetherlandsContact person changed (no phone or email listed)
    • Onze Lieve Vrouwe Gasthuis (OLVG) · Amsterdam, NetherlandsContact added (no phone or email listed)
    • Rijnstate · Arnhem, NetherlandsContact added (no phone or email listed)
    • Amphia ziekenhuis · Breda, NetherlandsContact added (no phone or email listed)
    • Deventer Ziekenhuis · Deventer, NetherlandsContact added (no phone or email listed)
    • Ziekenhuis Gelderse Vallei · Ede, NetherlandsContact added (no phone or email listed)
    • Catharina Ziekenhuis · Eindhoven, NetherlandsContact added (no phone or email listed)
    • Jeroen Bosch ziekenhuis · Eindhoven, NetherlandsContact added (no phone or email listed)
    • St. Jansdal · Harderwijk, NetherlandsContact added (no phone or email listed)
    • Ziekenhuisgroep Twente · Hengelo, NetherlandsContact added (no phone or email listed)
    • Tergooi ziekenhuizen · Hilversum, NetherlandsContact added (no phone or email listed)
    • Spaarne Gasthuis · Hoofddorp, NetherlandsContact added (no phone or email listed)
    • Dijklander ziekenhuis · Hoorn, NetherlandsContact added (no phone or email listed)
    • MCL · Leeuwarden, NetherlandsContact added (no phone or email listed)
    • LUMC · Leiden, NetherlandsContact added (no phone or email listed)
    • MUMC · Maastricht, NetherlandsContact added (no phone or email listed)
    • St. Antonius ziekenhuis · Nieuwegein, NetherlandsContact added (no phone or email listed)
    • Erasmus Medical Center Cancer Institute · Rotterdam, NetherlandsContact added (no phone or email listed)
    • VieCuri Medisch Centrum voor Noord-Limburg · Venlo, NetherlandsContact added (no phone or email listed)
    • Isala · Zwolle, NetherlandsContact added (no phone or email listed)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06476119
Collaborators
Maarten van de Weijden Foundation, AVL Foundation, Dutch Cancer Society
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Apr 15, 2025
Primary completion
Sep 15, 2032 (estimated)
Completion
Sep 15, 2034 (estimated)
Last update
Nov 16, 2026

Study contacts

Marleen Kok, MD
Contact
m.kok@nki.nl
+31205129111
Rianne Rolfes, MD
Contact
r.rolfes@nki.nl
+31205129111
Marleen Kok, MD
principal investigator · Antoni van Leeuwenhoek

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion